{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:26:14Z","timestamp":1791897974984,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd011798","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000}}],"reference-count":602,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011798.pub2","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T12:30:29Z","timestamp":1537792229000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease"],"prefix":"10.1002","author":[{"given":"Clement","family":"Lo","sequence":"first","affiliation":[{"name":"Monash University; Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine; Clayton VIC Australia"},{"name":"Monash Health; Diabetes and Vascular Medicine Unit; Clayton VIC Australia"},{"name":"Monash University; Division of Metabolism, Ageing and Genomics, School of Public Health and Preventive Medicine; Prahan VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney; Renal and Metabolic Division; Newtown NSW Australia 2050"},{"name":"Kanazawa University Hospital; Division of Nephrology; Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney; Renal and Metabolic Division; Newtown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lin","sequence":"additional","affiliation":[{"name":"Beijing Friendship Hospital, Capital Medical University; Department of Critical Care Medicine; 95 Yong-An Road, Xuan Wu District Beijing China 100050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney; Professorial Unit; Newtown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jun","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney; Renal and Metabolic Division; Newtown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cass","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research; PO Box 41096 Casuarina NT Australia 0811"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M","family":"Hawley","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital; Department of Nephrology; Ipswich Road Woolloongabba QLD Australia 4102"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pilmore","sequence":"additional","affiliation":[{"name":"Auckland Hospital; Department of Renal Medicine; Park Road Grafton Auckland New Zealand"},{"name":"University of Auckland; Department of Medicine; Grafton New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V","family":"Badve","sequence":"additional","affiliation":[{"name":"St George Hospital; Department of Renal Medicine; Kogarah NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney; Renal and Metabolic Division; Newtown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[{"name":"Monash Health; Diabetes and Vascular Medicine Unit; Clayton VIC Australia"},{"name":"Monash University; Division of Metabolism, Ageing and Genomics, School of Public Health and Preventive Medicine; Prahan VIC Australia"},{"name":"The George Institute for Global Health, UNSW Sydney; Professorial Unit; Newtown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5414\/CNP68287","article-title":"Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis","volume":"68","author":"Abe","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5414\/CNP70220","article-title":"Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis","volume":"70","author":"Abe","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/14656560903530683","article-title":"Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis","volume":"11","author":"Abe","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1517\/14656566.2010.495119","article-title":"Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis","volume":"11","author":"Abe","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.diabres.2016.04.034","article-title":"Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial","volume":"116","author":"Abe","year":"2016","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"i216","DOI":"10.1093\/ndt\/gfw169.01","article-title":"Efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitor in hemodialysis patients with type 2 diabetes [abstract]","volume":"31","author":"Abe","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011798.pub2-BIB0007|cit7","first-page":"65","article-title":"Efficacy and safety of saxagliptin, dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with type 2 diabetes [abstract]","volume":"21","author":"Abe","year":"2016","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Herz M Ruilope L Hanefeld M Lincoff AM Viberti G Reigner SM Effects of aleglitazar on renal function in patients with stage 3 chronic kidney disease and type-2 diabetes [abstract no: O22] British Transplantation Society & the Renal Association Joint Congress; 2013 Mar 13-15; Bournemouth, UK 2013","DOI":"10.1186\/1471-2369-15-180"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"E1173","DOI":"10.1016\/S0735-1097(13)61173-0","article-title":"Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type II diabetes [abstract]","volume":"10","author":"Malmberg","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2369-15-180","article-title":"Effects of the dual peroxisome proliferator-activated receptor-alpha\/gamma agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study","volume":"15","author":"Ruilope","year":"2014","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0011|cit11","first-page":"A281","article-title":"Consistency of the A1C-lowering effects of sitagliptin versus glipizide in patients with type 2 diabetes and chronic renal insufficiency across a variety of baseline characteristics [abstract]","volume":"61","author":"Arjona Ferreira","year":"2012","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0012|cit12","first-page":"A258","article-title":"Sitagliptin more effectively achieves a composite endpoint of a1c reduction, no body weight gain, and lack of hypoglycemia in patients with type 2 diabetes and renal insufficiency compared to glipizide [abstract]","volume":"61","author":"Arjona Ferreira","year":"2012","journal-title":"Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc12-1365","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency","volume":"36","author":"Arjona Ferreira","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0014|cit14","first-page":"419","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate to severe chronic renal insufficiency [abstract]","volume":"20","author":"Arjona Ferreira","year":"2011","journal-title":"Diabetes, Stoffwechsel und Herz"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0015|cit15","first-page":"8B","article-title":"Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and moderate to severe chronic renal insufficiency [abstract no: LB-PO3166]","volume":"22","author":"Arjona Ferreira","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0016|cit16","first-page":"S342","article-title":"Consistency of HbA1c-lowering effects of sitagliptin vs glipizide in patients with type 2 diabetes and chronic renal insufficiency across a variety of baseline characteristics [abstract]","volume":"55","author":"Engel","year":"2012","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial","volume":"61","author":"Arjona Ferreira","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0018|cit18","first-page":"430","article-title":"Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes mellitus and end-stage renal disease on dialysis: A 54-week randomised trial [abstract]","volume":"20","author":"Arjona Ferreira","year":"2011","journal-title":"Diabetes, Stoffwechsel und Herz"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0019|cit19","first-page":"8B","article-title":"Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and end-stage renal disease on dialysis [abstract no: LB-PO3167]","volume":"22","author":"Arjona Ferreira","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc12-0578","article-title":"A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency","volume":"35","author":"Baldwin","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0021|cit21","first-page":"A297","article-title":"Initial insulin doses should be decreased in hospitalized patients with renal insufficiency and type 2 diabetes [abstract]","volume":"60","author":"Zander","year":"2011","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0023|cit22","first-page":"102","article-title":"Efficacy and safety of linagliptin in elderly patients (.70 years) with type 2 diabetes mellitus [abstract no: OCS-05-3]","volume":"3","author":"Barnett","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"issue":"9902","key":"10.1002\/14651858.CD011798.pub2-BIB0022|cit23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(13)61500-7","article-title":"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Barnett","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1479164113507068","article-title":"Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment","volume":"11","author":"McGill","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0025|cit25","first-page":"S360","article-title":"Sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes and advanced chronic kidney disease [abstract]","volume":"59","author":"Bellante","year":"2016","journal-title":"Diabetologia"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2008.00914.x","article-title":"Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency","volume":"10","author":"Chan","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0027|cit27","first-page":"452","article-title":"Comparative randomized study of insulin administration through two different routes in CAPD diabetic patients [abstract]","volume":"2","author":"Diez","year":"1987","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0028|cit28","first-page":"296","article-title":"Comparative randomized study of insulin administration through two different routes in CAPD diabetic patients. [abstract]","volume":"34","author":"Diez","year":"1988","journal-title":"Kidney International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0029|cit29","first-page":"n\/a","article-title":"Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin in patients with type 2 diabetes and hypertension [abstract no: 16709]","volume":"130","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/01.hjh.0000467485.28062.c1","article-title":"Contrasting influences of renal function on blood pressure and hba1c reductions with empagliflozin in patients with type 2 diabetes and hypertension [abstract no: 4B.01]","volume":"33","author":"Cherney","year":"2015","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011798.pub2-BIB0034|cit34","first-page":"59","article-title":"Effect of empagliflozin on nephropathy in subgroups by age: Results from EMPA-REG OUTCOME [abstract]","volume":"21","author":"D'Emden","year":"2016","journal-title":"Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"A668","DOI":"10.1016\/j.jval.2016.09.1852","article-title":"Impact of empagliflozin (jardiance) to the NHS: Estimation of budget and event impact based on EMPA-REG OUTCOME data [abstract]","volume":"19","author":"Daacke","year":"2016","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0036|cit36","first-page":"S378","article-title":"Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus [abstract]","volume":"56","author":"Inzucchi","year":"2013","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0037|cit37","first-page":"S537","article-title":"Cardiovascular (CV) outcomes according to LDL cholesterol (LDLC) levels in EMPA-REG OUTCOME [abstract]","volume":"59","author":"Langslet","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0038|cit38","first-page":"1192","article-title":"Cardiovascular outcomes according to LDL cholesterol levels in EMPA-REG OUTCOME [abstract]","volume":"37","author":"Langslet","year":"2016","journal-title":"European Heart Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"iii12","DOI":"10.1093\/ndt\/gfx103","article-title":"Effects of empagliflozin on cardiovascular outcomes across KDIGO risk categories: results from the EMPA-REG OUTCOME trial [abstract]","volume":"32","author":"Perkovic","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0040|cit40","first-page":"A314","article-title":"Empagliflozin and progression of kidney disease in patients at high renal risk: Slope analyses from EMPA-REG OUTCOME [abstract]","volume":"66","author":"Wanner","year":"2017","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0041|cit41","first-page":"80","article-title":"Reduced progression of kidney disease with empagliflozin: Results from EMPA-REG OUTCOME [abstract]","volume":"34","author":"Wanner","year":"2017","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"iii193","DOI":"10.1093\/ndt\/gfx145.SP259","article-title":"Effects of empagliflozin on renal outcomes across KDIGO risk categories: Results from the EMPA-REG OUTCOME trial [abstract]","volume":"32","author":"Wanner","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"n\/a","DOI":"10.1055\/s-0034-1374995","article-title":"Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME) in patients with type 2 diabetes [abstract]","volume":"9","author":"Zinman","year":"2014","journal-title":"Diabetologie und Stoffwechsel"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0046|cit46","first-page":"A600","article-title":"Design of the empagliflozin cardiovascular (CV) outcome event trial in type 2 diabetes (T2D) [abstract]","volume":"62","author":"Zinman","year":"2013","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","article-title":"Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk","volume":"48","author":"Zinman","year":"2017","journal-title":"Stroke"},{"issue":"22","key":"10.1002\/14651858.CD011798.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0050|cit50","first-page":"S483","article-title":"Effect of empagliflozin on nephropathy in subgroups by age: Results from EMPA-REG OUTCOME [abstract]","volume":"59","author":"Eynatten","year":"2016","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0052|cit52","first-page":"S387","article-title":"Efficacy and safety of gemigliptin in type 2 diabetes patients with moderate to severe renal impairment [abstract no:804]","volume":"58","author":"Yoon","year":"2015","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0053|cit53","first-page":"S361","article-title":"Efficacy and safety of gemigliptin in type 2 diabetes patients with moderate to severe renal impairment (GUARD study) [abstract no: 760]","volume":"59","author":"Yoon","year":"2016","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12863","article-title":"Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)","volume":"19","author":"Yoon","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","article-title":"Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus","volume":"38","author":"Haneda","year":"2016","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2013-002764","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study","volume":"3","author":"Idorn","year":"2013","journal-title":"BMJ Open"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0057|cit57","first-page":"S370","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, randomised, placebo controlled trial [abstract]","volume":"57","author":"Idorn","year":"2014","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ11-0025","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"58","author":"Ito","year":"2011","journal-title":"Endocrine Journal"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/ndt\/gfm049","article-title":"Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy","volume":"22","author":"Jin","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000104089","article-title":"Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy","volume":"30","author":"Jin","year":"2007","journal-title":"Kidney & Blood Pressure Research"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.12325","article-title":"Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise","volume":"16","author":"Kaku","year":"2014","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0064|cit64","first-page":"232A","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract no:TH-PO524]","volume":"22","author":"Kohan","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s00125-015-3655-z","article-title":"Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial","volume":"58","author":"Kothny","year":"2015","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0066|cit66","first-page":"A264","article-title":"Long-term efficacy and safety of linagliptin in type 2 diabetes patients with moderate to severe renal disease","volume":"63","author":"Groop","year":"2014","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0067|cit67","first-page":"S364","article-title":"Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment [abstract no:P13-11527]","volume":"56","author":"Groop","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0068|cit68","first-page":"A281","article-title":"Linagliptin vs. placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment","volume":"62","author":"Laakso","year":"2013","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.2337\/dc14-1684","article-title":"Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial","volume":"38","author":"Laakso","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/dom.12403","article-title":"A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.clinthera.2012.07.008","article-title":"Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"34","author":"Lewin","year":"2012","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1479164113507068","article-title":"Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment","volume":"11","author":"McGill","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8227(14)70266-9","article-title":"Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial [abstract no: OP60]","volume":"106","author":"Mathieu","year":"2014","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jcjd.2014.07.020","article-title":"Efficacy and safety of liraglutide vs. placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL) [abstract no: 18]","volume":"38","author":"Ngo","year":"2014","journal-title":"Canadian Journal of Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0077|cit77","first-page":"S84","article-title":"Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial [abstract]","volume":"57","author":"Umpierrez","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0078|cit78","first-page":"S332","article-title":"Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR<30) [abstract]","volume":"54","author":"Kothny","year":"2011","journal-title":"Diabetologia"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1463-1326.2012.01634.x","article-title":"One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment","volume":"14","author":"Kothny","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0080|cit80","first-page":"A253","article-title":"One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes mellitus and moderate or severe renal insufficiency [abstract]","volume":"61","author":"Kothny","year":"2012","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0081|cit81","first-page":"S332","article-title":"Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment [abstract]","volume":"54","author":"Lukashevich","year":"2011","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/VHRM.S39300","article-title":"Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment","volume":"9","author":"Lukashevich","year":"2013","journal-title":"Vascular Health & Risk Management"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1463-1326.2011.01467.x","article-title":"Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial","volume":"13","author":"Lukashevich","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1479164113507068","article-title":"Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment","volume":"11","author":"McGill","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1479164115579001","article-title":"Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease","volume":"12","author":"McGill","year":"2015","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/ENDO:28:2:181","article-title":"The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease","volume":"28","author":"Mohideen","year":"2005","journal-title":"Endocrine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e000265","DOI":"10.1136\/bmjdrc-2016-000265","article-title":"Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial","volume":"4","author":"Mori","year":"2016","journal-title":"BMJ Open Diabetes Research & Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0089|cit89","first-page":"863","article-title":"Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes","volume":"23","author":"Nakamura","year":"2001","journal-title":"Renal Failure"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1742-1241.2011.02812.x","article-title":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study","volume":"65","author":"Nowicki","year":"2011","journal-title":"International Journal of Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01382.x","article-title":"Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment","volume":"13","author":"Nowicki","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0092|cit92","first-page":"A315","article-title":"Use of pioglitazone vs. placebo in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis treatment [abstract]","volume":"60","author":"Pfutzner","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2337\/diacare.26.2.502","article-title":"Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy","volume":"26","author":"Ruggenenti","year":"2003","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc15-2763","article-title":"Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 trial","volume":"39","author":"Cahn","year":"2016","journal-title":"Diabetes care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.2337\/dc15-0006","article-title":"Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705","volume":"38","author":"Kalra","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0096|cit96","first-page":"354","article-title":"Study on the risk reduction of cardiovascular events with saxagliptin in type 2 diabetic patients (SAVOR-TIMI 53): Study and patients description","volume":"7","author":"Krempf","year":"2013","journal-title":"Medecine des Maladies Metaboliques"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/dom.12582","article-title":"Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial","volume":"18","author":"Leiter","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes care"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/dmrr.2413","article-title":"Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial","volume":"29","author":"Mosenzon","year":"2013","journal-title":"Diabetes\/Metabolism Research Reviews"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0100|cit100","first-page":"S355","article-title":"Clinically significant change in albumin creatinine ratio with saxagliptin: A post hoc analysis from the SAVOR-TIMI 53 trial [abstract]","volume":"60","author":"Mosenzon","year":"2017","journal-title":"Diabetologia"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/dc15-1068","article-title":"Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial","volume":"38","author":"Mosenzon","year":"2015","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1002\/14651858.CD011798.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ahj.2011.08.006","article-title":"The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study","volume":"162","author":"Scirica","year":"2011","journal-title":"American Heart Journal"},{"issue":"18","key":"10.1002\/14651858.CD011798.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"issue":"22 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0105|cit105","first-page":"n\/a","article-title":"Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 study [abstract]","volume":"128","author":"Scirica","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/089686089401400206","article-title":"Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration","volume":"14","author":"Scarpioni","year":"1994","journal-title":"Peritoneal Dialysis International"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2337\/dc16-1135","article-title":"Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)","volume":"40","author":"Bethel","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc15-2780","article-title":"Pancreatic safety of sitagliptin in the TECOS study","volume":"40","author":"Buse","year":"2017","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2017","journal-title":"Diabetes care"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0111|cit111","first-page":"S361","article-title":"Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [abstract]","volume":"59","author":"Engel","year":"2016","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Aug 6;373(6):586; PMID: 26182233]","volume":"373","author":"Green","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","article-title":"Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease","volume":"166","author":"Green","year":"2013","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD011798.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.117.027252","article-title":"Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)","volume":"136","author":"Pagidipati","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2005.06.020","article-title":"Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis","volume":"46","author":"Wong","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0117|cit117","first-page":"220A","article-title":"Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (t2dm) and moderate renal impairment [abstract no:TH-PO536]","volume":"23","author":"Bakris","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0118|cit118","first-page":"S381","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes mellitus and chronic kidney disease over 52 weeks [abstract no: 951]","volume":"56","author":"Nieto Iglesias","year":"2013","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0119|cit119","first-page":"A277","article-title":"Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) over 52 weeks [abstract]","volume":"62","author":"Yale","year":"2013","journal-title":"Diabetes"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011798.pub2-BIB0120|cit120","first-page":"S27","article-title":"Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus T2DM) and chronic kidney disease (CKD) over 52 weeks [abstract no: 71]","volume":"37","author":"Yale","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0123|cit123","first-page":"S312","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control and is well tolerated in type 2 diabetes subjects with moderate renal impairment [abstract no:759]","volume":"55","author":"Yale","year":"2012","journal-title":"Diabetologia"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.jcjd.2012.07.344","article-title":"Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract no:139]","volume":"36","author":"Yale","year":"2012","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0125|cit125","doi-asserted-by":"crossref","unstructured":"Yale JF Bakris GL Cariou B Nieto Iglesias J Wajs E Figueroa K Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) over 52 weeks [abstract no: 0175-P] 73rd Scientific Sessions of the American Diabetes Association; 21-25 June 2013; Chicago, IL 2013","DOI":"10.1016\/j.jcjd.2013.08.082"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1185\/03007995.2015.1010638","article-title":"Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus","volume":"31","author":"Sheu","year":"2015","journal-title":"Current Medical Research & Opinion"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2337\/dc12-2718","article-title":"Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a \u226552-week randomized, double-blind study","volume":"36","author":"Yki-J\u00e4rvinen","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clinthera.2014.10.026","article-title":"LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion","volume":"37","author":"Zambrowicz","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0129|cit129","first-page":"233","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]","volume":"363","author":"Chew","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0133|cit133","first-page":"1563","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]","volume":"362","author":"Ginsberg","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD011798.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2337\/dc11-1827","article-title":"Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial","volume":"35","author":"Barzilay","year":"2012","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2215\/CJN.11321112","article-title":"Albuminuria and cognitive decline in people with diabetes and normal renal function","volume":"8","author":"Barzilay","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"80i","DOI":"10.1016\/j.amjcard.2007.03.026","article-title":"Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Bonds","year":"2007","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6823-12-5","article-title":"Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data","volume":"12","author":"Bonds","year":"2012","journal-title":"BMC Endocrine Disorders"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"103i","DOI":"10.1016\/j.amjcard.2007.03.028","article-title":"Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)","volume":"99","author":"Chew","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"44i","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.amjcard.2014.07.045","article-title":"Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)","volume":"114","author":"Fatemi","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dc12-1391","article-title":"Determinants of weight gain in the action to control cardiovascular risk in diabetes trial","volume":"36","author":"Fonseca","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1210\/jc.2011-1679","article-title":"Clinical implications of the ACCORD trial. [Review]","volume":"97","author":"Genuth","year":"2012","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2337\/dc12-1311","article-title":"Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial","volume":"36","author":"Gerstein","year":"2013","journal-title":"Diabetes Care"},{"issue":"9958","key":"10.1002\/14651858.CD011798.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(14)60611-5","article-title":"Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial","volume":"384","author":"Gerstein","year":"2014","journal-title":"Lancet"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"34i","DOI":"10.1016\/j.amjcard.2007.03.004","article-title":"Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Gerstein","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"56i","DOI":"10.1016\/j.amjcard.2007.03.024","article-title":"Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Ginsberg","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"4i","DOI":"10.1016\/j.amjcard.2007.03.002","article-title":"Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Goff","year":"2007","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bone.2015.04.037","article-title":"Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial","volume":"78","author":"Isakova","year":"2015 Sep","journal-title":"Bone"},{"issue":"9739","key":"10.1002\/14651858.CD011798.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Ismail-Beigi F Craven TE O'Connor PJ Karl D Calles-Escandon J Hramiak I Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients Kidney International 2012 586 94 22166848","DOI":"10.1038\/ki.2011.415"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"68i","DOI":"10.1016\/j.amjcard.2007.03.025","article-title":"Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Kingry","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc13-0790","article-title":"Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial","volume":"37","author":"Linz","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2337\/dc13-2334","article-title":"Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial","volume":"37","author":"Margolis","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2147\/VHRM.S4808","article-title":"Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies","volume":"5","author":"Meier","year":"2009","journal-title":"Vascular Health & Risk Management"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"b5444","DOI":"10.1136\/bmj.b5444","article-title":"The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study","volume":"340","author":"Miller","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/dc13-1545","article-title":"Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial","volume":"37","author":"Miller","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jdiacomp.2014.07.001","article-title":"The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial","volume":"28","author":"Mottl","year":"2014","journal-title":"Journal of Diabetes & its Complications"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0160|cit160","doi-asserted-by":"crossref","unstructured":"Mychaleckyj JC Craven T Nayak U Buse J Crouse JR Elam M Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants Diabetes Care 2012 1008 14 22432114","DOI":"10.2337\/dc11-1811"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1479-5876-9-91","article-title":"Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage","volume":"9","author":"Mychaleckyj","year":"2011","journal-title":"Journal of Translational Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2215\/CJN.12051115","article-title":"Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial","volume":"11","author":"Nadkarni","year":"2016","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000446122","article-title":"Cardiovascular outcomes in action to control cardiovascular risk in diabetes: impact of blood pressure level and presence of kidney disease","volume":"43","author":"Papademetriou","year":"2016","journal-title":"American Journal of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2337\/dc10-0125","article-title":"Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2337\/dc11-1855","article-title":"Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial","volume":"35","author":"Punthakee","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1475-2840-11-35","article-title":"Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial","volume":"11","author":"Raisch","year":"2012","journal-title":"Cardiovascular Diabetology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2337\/dc11-2556","article-title":"Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial","volume":"36","author":"Reyes-Soffer","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/dc09-1278","article-title":"Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial","volume":"33","author":"Riddle","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.diabres.2011.09.027","article-title":"The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers","volume":"95","author":"Samaropoulos","year":"2012","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2337\/dc11-0996","article-title":"The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study","volume":"35","author":"Seaquist","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/1740774510372779","article-title":"Evaluation of an automated method to assist with error detection in the ACCORD central laboratory","volume":"7","author":"Strylewicz","year":"2010","journal-title":"Clinical Trials"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"90i","DOI":"10.1016\/j.amjcard.2007.03.027","article-title":"Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design","volume":"99","author":"Sullivan","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.2337\/dc11-1791","article-title":"Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy","volume":"35","author":"Sullivan","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1373\/clinchem.2010.155887","article-title":"Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial","volume":"57","author":"Thethi","year":"2011","journal-title":"Clinical Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamainternmed.2013.13656","article-title":"Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial","volume":"174","author":"Williamson","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"112i","DOI":"10.1016\/j.amjcard.2007.03.029","article-title":"The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods","volume":"99","author":"Williamson","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"23","key":"10.1002\/14651858.CD011798.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.[erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]","volume":"355","author":"Kahn","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2337\/db06-0116","article-title":"Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes","volume":"55","author":"Kahn","year":"2006","journal-title":"Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.09291010","article-title":"Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy","volume":"6","author":"Lachin","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.2337\/diabetes.53.12.3193","article-title":"Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe","volume":"53","author":"Zinman","year":"2004","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0200|cit182","first-page":"S21","article-title":"Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation","volume":"19","year":"2001","journal-title":"Journal of Hypertension - Supplement"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0201|cit183","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s001250100612","article-title":"Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation","volume":"44","year":"2001","journal-title":"Diabetologia"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0183|cit184","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-5491.2005.01596.x","article-title":"ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline","volume":"22","author":"ADVANCE Collaborative Group","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"24","key":"10.1002\/14651858.CD011798.pub2-BIB0182|cit185","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"Spec No 1","key":"10.1002\/14651858.CD011798.pub2-BIB0185|cit186","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003495-200363991-00005","article-title":"[ADVANCE study: objectives, design and current status]. [French]","volume":"63","author":"Chalmers","year":"2003","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0184|cit187","first-page":"S354","article-title":"The efficacy of lowering HbAlc with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial [abstract]","volume":"52","author":"Chalmers","year":"2009","journal-title":"Diabetologia"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0186|cit188","first-page":"S442","article-title":"Risk of major renal events in people with type 2 diabetes: Prediction models based on the ADVANCE study population [abstract]","volume":"54","author":"Cooper","year":"2011","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0187|cit189","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/CIRCULATIONAHA.113.002717","article-title":"Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial","volume":"128","author":"Hata","year":"2013","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD011798.pub2-BIB0188|cit190","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1093\/eurheartj\/ehq139","article-title":"Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease","volume":"31","author":"Heerspink","year":"2010","journal-title":"European Heart Journal"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD011798.pub2-BIB0189|cit191","first-page":"543A","article-title":"Predictive baseline factors for major renal events: a proportional hazards model based on the Advance Study [abstract no: F-PO1916]","volume":"19","author":"Jardine","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0190|cit192","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2012.04.025","article-title":"Prediction of kidney-related outcomes in patients with type 2 diabetes","volume":"60","author":"Jardine","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0191|cit193","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/dc16-1594","article-title":"Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes","volume":"39","author":"Mohammedi","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0192|cit194","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/HJH.0b013e328338a89c","article-title":"Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial","volume":"28","author":"Ninomiya","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0193|cit195","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/sj.jhh.1001890","article-title":"ADVANCE: Action in diabetes and vascular disease","volume":"19","author":"Patel","year":"2005","journal-title":"Journal of Human Hypertension"},{"issue":"9590","key":"10.1002\/14651858.CD011798.pub2-BIB0194|cit196","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0195|cit197","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0196|cit198","unstructured":"Perkovic V Ninomiya T de Galan BE Zoungas S Cass A Patel A Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB-002] American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia, PA 2008"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0197|cit199","first-page":"42","article-title":"Intensive glucose lowering and end stage kidney disease - new data from the ADVANCE trial [abstract no: 071]","volume":"16","author":"Perkovic","year":"2011","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0198|cit200","first-page":"A121","article-title":"Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]","volume":"13","author":"Perkovic","year":"2008","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0199|cit201","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000354417.70192.be","article-title":"Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE","volume":"27 Suppl 1","author":"Poulter","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1093\/ndt\/gfs022","article-title":"The risk of cancer in people with diabetes and chronic kidney disease","volume":"27","author":"Wong","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016 May","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-011-2404-1","article-title":"Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds","volume":"55","author":"Zoungas","year":"2012","journal-title":"Diabetologia"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0205|cit205","first-page":"S23","article-title":"Intensive glucose lowering and end stage kidney disease: New data from the ADVANCE trial [abstract]","volume":"54","author":"Zoungas","year":"2011","journal-title":"Diabetologia"},{"issue":"15","key":"10.1002\/14651858.CD011798.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0207|cit207","first-page":"1103","article-title":"Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]","volume":"53","author":"Zoungas","year":"2009","journal-title":"Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.2337\/dc09-0959","article-title":"Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial","volume":"32","author":"Zoungas","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0209|cit209","first-page":"A218","article-title":"Renoprotective effects of blood pressure lowering with perindopril-indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]","volume":"57","author":"Galan","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1681\/ASN.2008070667","article-title":"Lowering blood pressure reduces renal events in type 2 diabetes","volume":"20","author":"Galan","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0212|cit211","doi-asserted-by":"crossref","first-page":"F600","DOI":"10.1152\/ajprenal.00289.2005","article-title":"Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy","volume":"290","author":"Agarwal","year":"2006","journal-title":"American Journal of Physiology - Renal Physiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0211|cit212","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00416.x","article-title":"A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjmed.2003.07.023","article-title":"Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial","volume":"116","author":"Aljabri","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0188-4409(00)00241-1","article-title":"The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus","volume":"31","author":"Amador-Licona","year":"2000","journal-title":"Archives of Medical Research"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2337\/diacare.18.9.1260","article-title":"Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy","volume":"18","author":"Aoki","year":"1995","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10157-011-0512-3","article-title":"Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study","volume":"15","author":"Morikawa","year":"2011","journal-title":"Clinical & Experimental Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/01.hjh.0000244955.39491.88","article-title":"Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria","volume":"24","author":"Bakris","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0220|cit218","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF02743268","article-title":"Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria","volume":"36","author":"Bangstad","year":"1993","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0218|cit219","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/BF00401371","article-title":"Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic patients with microalbuminuria","volume":"35","author":"Bangstad","year":"1992","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0219|cit220","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s001250050136","article-title":"Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy","volume":"37","author":"Bangstad","year":"1994","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2337\/diacare.21.8.1295","article-title":"Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria","volume":"21","author":"Berg","year":"1998","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0222|cit222","first-page":"S378","article-title":"Effects of glucose control on renal tubular and glomerular functions in incipient IDDM nephropathy [abstract]","volume":"3","author":"Hartmann","year":"1997","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ahj.2012.06.017","article-title":"Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","volume":"164","author":"Abbott","year":"2012","journal-title":"American Heart Journal"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"41G","DOI":"10.1016\/j.amjcard.2006.03.012","article-title":"Modifications of coronary risk factors","volume":"97","author":"Albu","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/oby.2009.339","article-title":"Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"18","author":"Albu","year":"2010","journal-title":"Obesity"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.2337\/dc12-2265","article-title":"Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"36","author":"Althouse","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.12281211","article-title":"Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study","volume":"9","author":"August","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.112.000678","article-title":"Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"128","author":"Bach","year":"2013","journal-title":"Circulation"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"31G","DOI":"10.1016\/j.amjcard.2006.03.011","article-title":"Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial","volume":"97","author":"Barsness","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ahj.2010.12.013","article-title":"The impact of race\/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","volume":"161","author":"Beohar","year":"2011","journal-title":"American Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.amjcard.2013.05.071","article-title":"Race\/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial","volume":"112","author":"Beohar","year":"2013","journal-title":"American Journal of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1161\/CIRCULATIONAHA.112.092973","article-title":"Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"126","author":"Brooks","year":"2012","journal-title":"Circulation"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/CIRCULATIONAHA.109.912642","article-title":"Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","volume":"122","author":"Brooks","year":"2010","journal-title":"Circulation"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"9G","DOI":"10.1016\/j.amjcard.2006.02.023","article-title":"Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial","volume":"97","author":"Brooks","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ahj.2008.05.015","article-title":"Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"156","author":"Bypass","year":"2008","journal-title":"American Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD011798.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1161\/CIRCULATIONAHA.109.913111","article-title":"The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.[Erratum appears in Circulation. 2010 Mar 30;121(12):e254]","volume":"120","author":"Chaitman","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2011.05.020","article-title":"The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes)","volume":"58","author":"Chung","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ahj.2011.03.019","article-title":"Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D)","volume":"162","author":"Chung","year":"2011","journal-title":"American Heart Journal"},{"issue":"13","key":"10.1002\/14651858.CD011798.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIRCULATIONAHA.111.029173","article-title":"Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial","volume":"124","author":"Cresci","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacc.2012.11.036","article-title":"Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial","volume":"61","author":"Dagenais","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD011798.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1161\/CIRCULATIONAHA.110.978247","article-title":"Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease","volume":"123","author":"Dagenais","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4065\/mcp.2009.0265","article-title":"Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study","volume":"85","author":"Escobedo","year":"2010","journal-title":"Mayo Clinic Proceedings"},{"issue":"15","key":"10.1002\/14651858.CD011798.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jacc.2013.01.044","article-title":"Risk factor control for coronary artery disease secondary prevention in large randomized trials","volume":"61","author":"Farkouh","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0145721710374653","article-title":"Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"36","author":"Grogan","year":"2010 Sep","journal-title":"Diabetes Educator"},{"issue":"25","key":"10.1002\/14651858.CD011798.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/CIRCULATIONAHA.109.912709","article-title":"Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","volume":"120","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"59G","DOI":"10.1016\/j.amjcard.2006.03.014","article-title":"Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease","volume":"97","author":"Hlatky","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nuclcard.2005.10.002","article-title":"Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in the BARI 2D trial: an initial report from the Nuclear Core Laboratory","volume":"13","author":"Iskandrian","year":"2006","journal-title":"Journal of Nuclear Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0248|cit248","first-page":"384","article-title":"Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial","volume":"2","author":"Kim","year":"2009","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0249|cit249","first-page":"384","article-title":"Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial","volume":"2","author":"Kim","year":"2009","journal-title":"Jacc: Cardiovascular Interventions"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2011.08.004","article-title":"Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial)","volume":"109","author":"Krishnaswami","year":"2012","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2011.08.004","article-title":"Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial)","volume":"109","author":"Krishnaswami","year":"2012","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0252|cit252","first-page":"711","article-title":"[The BARI 2D study]. [Italian]","volume":"11","author":"Mafrici","year":"2010","journal-title":"Giornale Italiano di Cardiologia"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"20G","DOI":"10.1016\/j.amjcard.2006.02.024","article-title":"Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial","volume":"97","author":"Magee","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjcard.2009.08.643","article-title":"Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial)","volume":"105","author":"McBane","year":"2010","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1751-7141.2008.00014.x","article-title":"Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"12","author":"Pambianco","year":"2009","journal-title":"Preventive Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2009.02.046","article-title":"Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study)","volume":"104","author":"Pop-Busui","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2009.00200.x","article-title":"Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort","volume":"14","author":"Pop-Busui","year":"2009","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0259|cit259","first-page":"112","article-title":"Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial","volume":"13","author":"Rana","year":"2010","journal-title":"Preventive Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2337\/dc08-1308","article-title":"Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy","volume":"32","author":"Schneider","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0261|cit261","first-page":"166","article-title":"Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)","volume":"5","author":"Schwartz","year":"2012","journal-title":"Circulation: Cardiovascular Interventions"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjcard.2008.11.024","article-title":"Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D)","volume":"103","author":"Schwartz","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjcard.2008.11.024","article-title":"Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D)","volume":"103","author":"Schwartz","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ahj.2013.05.017","article-title":"Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","volume":"166","author":"Shah","year":"2013 Sep","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12350-012-9548-3","article-title":"Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"19","author":"Shaw","year":"2012","journal-title":"Journal of Nuclear Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/dc10-1734","article-title":"The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"34","author":"Singh","year":"2011","journal-title":"Diabetes Care"},{"issue":"12A","key":"10.1002\/14651858.CD011798.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"53G","DOI":"10.1016\/j.amjcard.2006.03.013","article-title":"Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities","volume":"97","author":"Sobel","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/CIRCULATIONAHA.110.014860","article-title":"Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"124","author":"Sobel","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjcard.2010.11.020","article-title":"Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2 Diabetes trial)","volume":"107","author":"Tamis-Holland","year":"2011","journal-title":"American Journal of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.jacc.2013.01.062","article-title":"Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes)","volume":"61","author":"Tamis-Holland","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.2105\/AJPH.2009.176180","article-title":"Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial","volume":"100 Suppl 1","author":"Thomas","year":"2010","journal-title":"American Journal of Public Health"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MAJ.0b013e3181d430ad","article-title":"High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data","volume":"339","author":"Wall","year":"2010","journal-title":"American Journal of the Medical Sciences"},{"issue":"8390","key":"10.1002\/14651858.CD011798.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(84)91820-8","article-title":"Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes","volume":"1","author":"Barnett","year":"1984","journal-title":"Lancet"},{"issue":"9896","key":"10.1002\/14651858.CD011798.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0276|cit276","first-page":"S28","article-title":"Canagliflozin slows progression of renal function decline independent of glycaemic effects [abstract]","volume":"59","author":"Heerspink","year":"2016","journal-title":"Diabetologia"},{"issue":"18","key":"10.1002\/14651858.CD011798.pub2-BIB0277|cit277","first-page":"1484","article-title":"The effects of pioglitazone on urinary albumin in excretion rate of early diabetic nephropathy","volume":"8","author":"Cao","year":"2005","journal-title":"Chinese General Practice"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1742-1241.2009.02143.x","article-title":"Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.[Erratum appears in Int J Clin Pract. 2010 Jan;64(2):277]","volume":"63","author":"Chacra","year":"2009","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0279|cit279","first-page":"50","article-title":"Clinical observation of pioglitazone in diabetic nephropathy","volume":"10","author":"Chen","year":"2004","journal-title":"International Medical Healthcare Guiding Journal"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0280|cit280","first-page":"1194","article-title":"Observation on the therapeutic effect of rosiglitazone combined with metformin on diabetic nephropathy","volume":"6","author":"Chen","year":"2006","journal-title":"China Tropical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1464-5491.1986.tb00701.x","article-title":"The effect of six months continuous subcutaneous insulin infusion on kidney function and size in insulin-dependent diabetics","volume":"3","author":"Christensen","year":"1986 Jan","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00365510151067965","article-title":"The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes","volume":"61","author":"Christensen","year":"2001 Feb","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0283|cit283","first-page":"738A","article-title":"The effect of low-flux and high-flux dialysers on endothelial dysfunction, oxidative stress and insulin resistance [abstract no: SA-PO774]","volume":"17","author":"Chu","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000117440","article-title":"Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance","volume":"26","author":"Chu","year":"2008","journal-title":"Blood Purification"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0285|cit285","first-page":"3","article-title":"Effect of long-term near-normoglycemia on the progression of diabetic nephropathy","volume":"11","author":"Ciavarella","year":"1985 Feb","journal-title":"Diabete et Metabolisme"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1053\/meta.2000.17700","article-title":"Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy","volume":"49","author":"Dailey","year":"2000","journal-title":"Metabolism - Clinical & Experimental"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.metabol.2008.11.005","article-title":"A pilot study to assess utility of changes in elements of the Diabetes Impact Management Scale in evaluating diabetic patients for progressive nephropathy","volume":"58","author":"Weinrauch","year":"2009","journal-title":"Metabolism - Clinical & Experimental"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.metabol.2008.11.006","article-title":"Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit","volume":"58","author":"Weinrauch","year":"2009","journal-title":"Metabolism - Clinical & Experimental"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.metabol.2007.05.016","article-title":"A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria","volume":"56","author":"Weinrauch","year":"2007 Nov","journal-title":"Metabolism - Clinical & Experimental"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.clinthera.2007.09.011","article-title":"A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy","volume":"29","author":"Davidson","year":"2007 Sep","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/db07-1059","article-title":"Multiple superoxide dismutase 1\/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Genetics study","volume":"57","author":"Al-Kateb","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2337\/diacare.13.4.427","article-title":"Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group","volume":"13","author":"Anonymous","year":"1990","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.10.1.1","article-title":"Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group","volume":"10","author":"Anonymous","year":"1987","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3476(94)70190-3","article-title":"Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group","volume":"125","author":"Anonymous","year":"1994","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ki.1995.236","article-title":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group","volume":"47","author":"Anonymous","year":"1995","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diab.35.5.530","article-title":"The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group","volume":"35","author":"Anonymous","year":"1986","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study","volume":"2","author":"DCCT\/EDIC Research Group","year":"2014","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"18","key":"10.1002\/14651858.CD011798.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1409463","article-title":"Intensive diabetes therapy and ocular surgery in type 1 diabetes","volume":"372","author":"Aiello","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD011798.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"Boer","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD011798.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","article-title":"Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005)","volume":"169","author":"Nathan","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0301|cit301","first-page":"381","article-title":"Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]","volume":"342","author":"Lachin","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mrm.22716","article-title":"T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison","volume":"65","author":"Gai","year":"2011","journal-title":"Magnetic Resonance in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/dc13-2148","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions","volume":"37","author":"Gubitosi-Klug","year":"2014","journal-title":"Diabetes Care"},{"issue":"1-2","key":"10.1002\/14651858.CD011798.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneuroim.2007.01.009","article-title":"Antibodies to GAD65 and peripheral nerve function in the DCCT","volume":"185","author":"Hoeldtke","year":"2007","journal-title":"Journal of Neuroimmunology"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.2337\/dc12-2109","article-title":"The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"36","author":"Jacobson","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jdiacomp.2013.06.002","article-title":"Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications cohort","volume":"27","author":"Jenkins","year":"2013","journal-title":"Journal of Diabetes & its Complications"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2337\/dc08-0864","article-title":"A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial","volume":"31","author":"Kilpatrick","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2337\/dc13-1746","article-title":"Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) cohort","volume":"37","author":"Kim","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.metabol.2014.07.001","article-title":"Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes","volume":"63","author":"Klein","year":"2014","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/dme.12296","article-title":"Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial","volume":"30","author":"Kramer","year":"2013","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc16-0857","article-title":"Association between blood pressure and adverse renal events in type 1 diabetes","volume":"39","author":"Ku","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/dc16-2426","article-title":"Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial","volume":"40","author":"Lachin","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2337\/db13-0881","article-title":"Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial","volume":"63","author":"Lachin","year":"2014","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1464-5491.2010.02972.x","article-title":"Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT\/EDIC","volume":"27","author":"Larkin","year":"2010","journal-title":"Diabetic Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2337\/dc09-2245","article-title":"Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial","volume":"33","author":"Lee","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1681\/ASN.V451159","article-title":"Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group","volume":"4","author":"Levey","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0317|cit317","first-page":"325","article-title":"Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F-PO1015]","volume":"18","author":"Lin","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc12-2521","article-title":"Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects","volume":"36","author":"Lopes-Virella","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/gfr454","article-title":"High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes","volume":"27","author":"Lopes-Virella","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/dme.12504","article-title":"Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)\/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study","volume":"31","author":"McGee","year":"2014","journal-title":"Diabetic Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2337\/dc09-1098","article-title":"Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study","volume":"33","author":"Molitch","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1373\/clinchem.2010.150250","article-title":"Determining stability of stored samples retrospectively: the validation of glycated albumin","volume":"57","author":"Nathan","year":"2011","journal-title":"Clinical Chemistry"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2337\/db10-0296","article-title":"Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) study","volume":"60","author":"Polak","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0197-2456(93)90048-I","article-title":"Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience","volume":"14","author":"Siebert","year":"1993","journal-title":"Controlled Clinical Trials"},{"issue":"Oct","key":"10.1002\/14651858.CD011798.pub2-BIB0325|cit325","first-page":"569A","article-title":"The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU-PO169]","volume":"15","author":"Tello","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"16","key":"10.1002\/14651858.CD011798.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1161\/CIRCULATIONAHA.111.022327","article-title":"Myocardial structure, function, and scar in patients with type 1 diabetes mellitus","volume":"124","author":"Turkbey","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archopht.126.12.1707","article-title":"Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial","volume":"126","author":"White","year":"2008","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/db09-1216","article-title":"Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT\/EDIC: comparison of adults and adolescents","volume":"59","author":"White","year":"2010","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2215\/CJN.07901109","article-title":"Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"5","author":"Younes","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1681\/ASN.2013091004","article-title":"Renal outcomes in patients with type 1 diabetes and macroalbuminuria","volume":"25","author":"Boer","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"171","author":"Boer","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0332|cit332","first-page":"2B","article-title":"Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT\/EDIC [Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB-OR05]","volume":"22","author":"Boer","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ki.2012.311","article-title":"Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease","volume":"83","author":"Boer","year":"2013","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0335|cit335","first-page":"143","article-title":"Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin","volume":"17","author":"Derosa","year":"2004","journal-title":"Diabetes, Nutrition & Metabolism - Clinical & Experimental"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1046\/j.1464-5491.2002.00811.x","article-title":"A time-limited, problem-orientated psychotherapeutic intervention in Type 1 diabetic patients with complications: a randomized controlled trial","volume":"19","author":"Didjurgeit","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8227(00)00203-5","article-title":"Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function","volume":"51","author":"Mauro","year":"2001","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diabres.2009.09.025","article-title":"Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): rationale and study design","volume":"87","author":"Shikata","year":"2010","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0149-2918(00)83039-8","article-title":"Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group","volume":"22","author":"Einhorn","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1210\/jc.2015-3716","article-title":"Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes","volume":"101","author":"Fadini","year":"2016","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0341|cit341","first-page":"555","article-title":"Observation of treatment effect of pioglitazone in diabetic kidney disease","volume":"19","author":"Fang","year":"2007","journal-title":"Modern Practical Medicine"},{"issue":"8519","key":"10.1002\/14651858.CD011798.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(86)91433-9","article-title":"Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes","volume":"2","author":"Feldt-Rasmussen","year":"1986","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM198603133141101","article-title":"Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy","volume":"314","author":"Feldt-Rasmussen","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1758-5996-4-36","article-title":"The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"4","author":"Frederich","year":"2012","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"Sept","key":"10.1002\/14651858.CD011798.pub2-BIB0345|cit345","first-page":"347A","article-title":"Role of metformin in treatment of hypertension in patients with insulin resistance mediated hypertension [abstract]","volume":"11","author":"Gadallah","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0346|cit346","first-page":"45","article-title":"Observation of therapeutic effects of rosiglitazone in type2 diabetic nephropathy","volume":"24","author":"Gan","year":"2007","journal-title":"Chinese Medical Journal of Metallurgical Industry"},{"issue":"20","key":"10.1002\/14651858.CD011798.pub2-BIB0347|cit347","first-page":"1497","article-title":"Short-term improvement effects of pioglitazone combined prostaglandin E1 in diabetic nephropathy","volume":"21","author":"Gao","year":"2006","journal-title":"Clinical Focus"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0348|cit348","first-page":"126","article-title":"Effects of rosiglitazone on urinary albumin excretion in patients with early diabetic nephropathy","volume":"15","author":"Gao","year":"2007","journal-title":"Zhong Guo Man Xing Bing Yu Fang Yu Kong Zhi [Chinese Journal of Prevention and Control of Chronic Non-communicable Diseases]"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0349|cit349","first-page":"176","article-title":"Pioglitazone combined fosinopril in treating 52 patients with type 2 diabetes and microalbuminuria","volume":"17","author":"Gao","year":"2007","journal-title":"Journal of New Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdiacomp.2004.07.003","article-title":"The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial","volume":"19","author":"Bakris","year":"2005","journal-title":"Journal of Diabetes & its Complications"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1161\/01.HYP.0000190585.54734.48","article-title":"Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes","volume":"46","author":"Bakris","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0352|cit352","first-page":"170","article-title":"Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study","volume":"22","author":"Goicolea","year":"2002","journal-title":"Nefrologia"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0353|cit353","first-page":"704","article-title":"Observation of therapeutic effects of pioglitazone in early diabetic nephropathy","volume":"20","author":"He","year":"2004","journal-title":"Journal of Practical Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone","volume":"94","author":"Hollander","year":"2009","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"8318","key":"10.1002\/14651858.CD011798.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(83)92586-2","article-title":"Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study","volume":"1","author":"Holman","year":"1983","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD011798.pub2-BIB0356|cit356","first-page":"27","article-title":"Effect of rosiglitazone on serum CRP and plasma PAI-1 in patients with early type 2 diabetic nephropathy","volume":"34","author":"Hu","year":"2007","journal-title":"Central Plains Medical Journal"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2362.2010.02302.x","article-title":"Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics","volume":"40","author":"Hu","year":"2010","journal-title":"European Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2265.2010.03878.x","article-title":"Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes","volume":"73","author":"Hu","year":"2010","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0359|cit359","first-page":"324","article-title":"Observation of therapeutic effects of rosiglitazone in diabetic nephropathy","volume":"17","author":"Huang","year":"2004","journal-title":"Acta Medicinae Sinica"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0360|cit360","first-page":"211","article-title":"Effect of rosiglitazone on urinary monocyte chemoattractant protein-1 in patients with diabetic nephropathy","volume":"25","author":"Huang","year":"2006","journal-title":"Journal of Yunyang Medical College"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0361|cit361","first-page":"51","article-title":"Effects of pioglitazone on changes of haemorrheology and insulin resistance in patients with early diabetic nephropathy","volume":"13","author":"Huang","year":"2007","journal-title":"IMHGN - International Medicine & Health Guidance News"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2337\/diacare.21.12.2135","article-title":"Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy","volume":"21","author":"Imano","year":"1998","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40261-014-0226-x","article-title":"Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment","volume":"34","author":"Inagaki","year":"2014","journal-title":"Clinical Drug Investigation"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0168-8227(87)80010-4","article-title":"Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study","volume":"3","author":"Jerums","year":"1987","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1600-079X.2006.00353.x","article-title":"Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin","volume":"41","author":"Kadhim","year":"2006","journal-title":"Journal of Pineal Research"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Advances in Therapy"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1681\/ASN.2006060606","article-title":"Effect of various diuretic treatments on rosiglitazone-induced fluid retention","volume":"17","author":"Karalliedde","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0368|cit368","first-page":"170","article-title":"Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy","volume":"89","author":"Katavetin","year":"2006","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"September, Prog","key":"10.1002\/14651858.CD011798.pub2-BIB0369|cit369","first-page":"41A","article-title":"Local and systemic effects of neutral pH, low GDP dialysate in CAPD patients [abstract no: SA-FC202]","volume":"13","author":"Do","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD011798.pub2-BIB0370|cit370","first-page":"374A","article-title":"The effect of low GDPs solution on peritoneal fibrosis markers [abstract no: SA-PO333]","volume":"15","author":"Park","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0371|cit371","first-page":"879","article-title":"Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?","volume":"48","author":"Kirk","year":"1999","journal-title":"Journal of Family Practice"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Research & Clinical Practice"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0373|cit373","first-page":"B21","article-title":"Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients","volume":"23 Suppl 2","author":"Shichiri","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8227(00)00122-4","article-title":"Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study","volume":"48","author":"Wake","year":"2000","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes.[Erratum appears in J Clin Endocrinol Metab. 2002 Feb;2(1):iv.], [Erratum appears in J Clin Endocrinol Metab 2001 Apr;86(4):1659]","volume":"86","author":"Lebovitz","year":"2001","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD011798.pub2-BIB0376|cit376","first-page":"341A","article-title":"Renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (BMS-512148) in patients with type 2 diabetes mellitus (T2DM) [abstract no: TH-PO1022]","volume":"19","author":"Leslie","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0377|cit377","first-page":"1432","article-title":"Observation of effect of rosiglitazone in type 2 diabetes with trace urinary protein","volume":"4","author":"Li","year":"2004","journal-title":"Zhong Guo Wu Zhen Xue Za Zhi [Chinese Journal of Misdiagnostics]"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0378|cit378","first-page":"31","article-title":"Effects of pioglitazone on microalbuminuria of early diabetic nephropathy","volume":"27","author":"Li","year":"2006","journal-title":"Journal of Medical Forum"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0379|cit379","first-page":"80","article-title":"Therapeutic effect of captopril combined with rosiglitazone on early diabetic nephropathy","volume":"7","author":"Li","year":"2008","journal-title":"Chinese Journal of Difficult & Complicated Cases"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0380|cit380","first-page":"58","article-title":"Rosiglitazone affect type 2 diabetic nephropathy","volume":"21","author":"Li","year":"2008","journal-title":"Zhong Guo Chang Kuang Yi Xue [Chinese Medicine of Factory and Mine]"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0381|cit381","first-page":"135","article-title":"Significance of intensive glycemic control on early diabetic nephropathy patients with microalbuminuria","volume":"22","author":"Lu","year":"2010","journal-title":"Academic Journal of Xi'an Jiaotong University"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-005-1751-1","article-title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","volume":"48","author":"Charbonnel","year":"2005","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","article-title":"Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study","volume":"21","author":"Matthews","year":"2005","journal-title":"Diabetes\/Metabolism Research Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.diabres.2011.05.008","article-title":"Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study","volume":"93","author":"Crasto","year":"2011","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0385|cit385","first-page":"166","article-title":"Impact of intensive multi-factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]","volume":"28","author":"Crasto","year":"2011","journal-title":"Diabetic Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0386|cit386","first-page":"160","article-title":"Interim analysis of the effects of a multifactorial intervention in people with Type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]","volume":"26","author":"Crasto","year":"2009","journal-title":"Diabetic Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.ki.5002516","article-title":"Rosiglitazone decreases albuminuria in type 2 diabetic patients","volume":"72","author":"Miyazaki","year":"2007","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"Journal of Diabetes & its Complications"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1464-5491.2001.00463.x","article-title":"Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria","volume":"18","author":"Nakamura","year":"2001","journal-title":"Diabetic Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.metabol.2004.05.013","article-title":"Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients","volume":"53","author":"Nakamura","year":"2004","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/dmrr.633","article-title":"Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria","volume":"22","author":"Nakamura","year":"2006","journal-title":"Diabetes\/Metabolism Research Reviews"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0392|cit392","unstructured":"Fogelfeld L Stroger JH Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy (ADN) www.clinicaltrials.gov\/ct2\/show\/NCT00708981"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0393|cit393","unstructured":"NCT01245166 A phase III randomized, double-blind, parallel-group study to evaluate the efficacy and safety of acarmet (metformin HCl 500 mg plus acarbose 50 mg tablets) versus acarbose alone in subjects with type 2 diabetes mellitus www.clinicaltrials.gov\/ct2\/show\/NCT01245166"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12325-016-0291-z","article-title":"Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus","volume":"33","author":"Jinnouchi","year":"2016","journal-title":"Advances in Therapy"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/dom.12481","article-title":"Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study","volume":"17","author":"Nishimura","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6556","key":"10.1002\/14651858.CD011798.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/bmj.293.6556.1195","article-title":"Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study","volume":"293","author":"Dahl-Jorgensen","year":"1986","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1530\/acta.0.1170019","article-title":"Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study","volume":"117","author":"Dahl-Jorgensen","year":"1988","journal-title":"Acta Endocrinologica"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2796.1998.00319.x","article-title":"Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group","volume":"244","author":"Ostman","year":"1998","journal-title":"Journal of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/dmrr.1306","article-title":"Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"28","author":"Pan","year":"2012","journal-title":"Diabetes\/Metabolism Research Reviews"},{"issue":"23-24","key":"10.1002\/14651858.CD011798.pub2-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00508-009-1279-3","article-title":"Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"121","author":"Petrica","year":"2009","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2337\/diacare.27.2.484","article-title":"In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control","volume":"27","author":"Pistrosch","year":"2004","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","article-title":"Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients","volume":"54","author":"Pistrosch","year":"2005","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0032-1314836","article-title":"Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy","volume":"44","author":"Pistrosch","year":"2012","journal-title":"Hormone & Metabolic Research"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.metabol.2010.01.004","article-title":"Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus","volume":"59","author":"Weinrauch","year":"2010","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/BF00400358","article-title":"Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus","volume":"36","author":"Pomerleau","year":"1993","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-005-1751-1","article-title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","volume":"48","author":"Charbonnel","year":"2005","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","article-title":"A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial","volume":"22","author":"Charbonnel","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.27.1.141","article-title":"One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes","volume":"27","author":"Hanefeld","year":"2004","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","article-title":"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.[Erratum appears in J Clin Endocrinol Metab. 2005 Feb;90(2):746]","volume":"89","author":"Schernthaner","year":"2004","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2369-14-80","article-title":"Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study","volume":"14","author":"Reinhard","year":"2013","journal-title":"BMC Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":"Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Current Medical Research & Opinion"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2796.1999.00402.x","article-title":"Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness","volume":"245","author":"Jensen-Urstad","year":"1999","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1365-2362.2003.01126.x","article-title":"Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima-media area, stiffness and diameter in Type 1 diabetes mellitus patients","volume":"33","author":"Johansson","year":"2003","journal-title":"European Journal of Clinical Investigation"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00125-014-3248-2","article-title":"Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long-term follow-up study","volume":"57","author":"Rathsman","year":"2014","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0424|cit415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0168-8227(92)90087-8","article-title":"Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS)","volume":"16","author":"Reichard","year":"1992","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0415|cit416","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2796.1991.tb00415.x","article-title":"Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years","volume":"230","author":"Reichard","year":"1991","journal-title":"Journal of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0416|cit417","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2796.1990.tb00271.x","article-title":"Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS)","volume":"228","author":"Reichard","year":"1990","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0417|cit418","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.0954-6820.1988.tb16748.x","article-title":"The Stockholm Diabetes Intervention Study (SDIS): 18 months' results","volume":"224","author":"Reichard","year":"1988","journal-title":"Acta Medica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0418|cit419","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1464-5491.2000.00398.x","article-title":"Autonomic neuropathy--a complication less pronounced in patients with Type 1 diabetes mellitus who have lower blood glucose levels","volume":"17","author":"Reichard","year":"2000","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0419|cit420","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199307293290502","article-title":"The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus","volume":"329","author":"Reichard","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/diab.43.2.313","article-title":"Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study","volume":"43","author":"Reichard","year":"1994","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0420|cit422","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s001250050602","article-title":"Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up","volume":"39","author":"Reichard","year":"1996","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0422|cit423","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2796.1989.tb01359.x","article-title":"Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy","volume":"226","author":"Reichard","year":"1989","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0423|cit424","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/014572179402000607","article-title":"Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS)","volume":"20","author":"Reichard","year":"1994","journal-title":"Diabetes Educator"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jdi.12316","article-title":"Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus","volume":"6","author":"Seino","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2010.08.037","article-title":"Effects of high dose aleglitazar on renal function in patients with type 2 diabetes","volume":"151","author":"Herz","year":"2011","journal-title":"International Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD011798.pub2-BIB0427|cit427","first-page":"2162","article-title":"Rosiglitazone in urinary protein of diabetic nephropathy","volume":"13","author":"Shata'er","year":"2007","journal-title":"Chinese Medicine Clinical Research - Chinese Magazine of Clinical Medicinal Professional Research"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5551\/jat.18333","article-title":"Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)","volume":"20","author":"Katakami","year":"2013","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial","volume":"63","author":"Stein","year":"2014","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD011798.pub2-BIB0431|cit431","first-page":"43A","article-title":"Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]","volume":"18","author":"Gaede","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2337\/dc07-2452","article-title":"Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study","volume":"31","author":"Gaede","year":"2008","journal-title":"Diabetes Care"},{"issue":"September, Prog","key":"10.1002\/14651858.CD011798.pub2-BIB0433|cit433","first-page":"72A","article-title":"The STENO-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC031]","volume":"13","author":"Gaede","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0434|cit434","unstructured":"Gaede P Vedel P Larsen N Jensen G Parving HH Pedersen O The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria [abstract no: 181] 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sep 1-5; Budapest, Hungary 2002"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0436|cit436","first-page":"1357","article-title":"Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]","volume":"7","author":"Gaede","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9153","key":"10.1002\/14651858.CD011798.pub2-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"issue":"30","key":"10.1002\/14651858.CD011798.pub2-BIB0438|cit438","first-page":"4277","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study","volume":"161","author":"Gaede","year":"1999","journal-title":"Ugeskrift for Laeger"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.kint.2016.11.023","article-title":"Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits Kidney Int. 2017;91:982-988.[Erratum appears in Kidney Int. 2017 May;91(5):1257; PMID: 28407880]","volume":"91","author":"Oellgaard","year":"2017","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0441|cit441","first-page":"593","article-title":"Pioglitazone affects the urinary protein extracting rate in early diabetic nephropathy","volume":"34","author":"Su","year":"2006","journal-title":"Youjiang Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0442|cit442","first-page":"101","article-title":"Effect of pioglitazone on serum advanced glycosylation end product peptide and monocyte chemoattractant protein-1 in type 2 diabetic patients","volume":"32","author":"Sun","year":"2006","journal-title":"Jiangsu Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0443|cit443","first-page":"176","article-title":"Observation of therapeutic effect of rosiglitazone in type 2 diabetes with nephropathy","volume":"12","author":"Tan","year":"2006","journal-title":"Journal of Modern Clinical Medical Bioengineering"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0444|cit444","first-page":"47","article-title":"Treatment effect of rosiglitazone in type 2 diabetic nephropathy","volume":"27","author":"Tang","year":"2007","journal-title":"Clinical Medicine"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1517\/14656566.2012.740459","article-title":"Black\/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin","volume":"13","author":"Thrasher","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD011798.pub2-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00011","article-title":"United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus","volume":"124","author":"Turner","year":"1996","journal-title":"Annals of Internal Medicine"},{"issue":"7160","key":"10.1002\/14651858.CD011798.pub2-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"7160","key":"10.1002\/14651858.CD011798.pub2-BIB0448|cit448","first-page":"703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.[Erratum appears in BMJ 1999 Jan 2;318(7175):29.]","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.1997.00440230053007","article-title":"Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes","volume":"157","author":"Abraira","year":"1997","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2337\/diacare.18.8.1113","article-title":"Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes","volume":"18","author":"Abraira","year":"1995","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2337\/diacare.15.11.1560","article-title":"Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM)","volume":"15","author":"Abraira","year":"1992","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2337\/diacare.21.4.574","article-title":"Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM)","volume":"21","author":"Abraira","year":"1998","journal-title":"Diabetes Care"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD011798.pub2-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/S0002-8703(99)70036-0","article-title":"Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial","volume":"138","author":"Abraira","year":"1999","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.21.4.510","article-title":"Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM)","volume":"21","author":"Agrawal","year":"1998","journal-title":"Diabetes Care"},{"issue":"5-6","key":"10.1002\/14651858.CD011798.pub2-BIB0455|cit455","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1056-8727(99)00062-8","article-title":"The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM)","volume":"13","author":"Azad","year":"1999","journal-title":"Journal of Diabetes & its Complications"},{"issue":"22","key":"10.1002\/14651858.CD011798.pub2-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1001\/archinte.158.22.2485","article-title":"Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus","volume":"158","author":"Emanuele","year":"1998","journal-title":"Archives of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2337\/diacare.19.12.1375","article-title":"Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study","volume":"19","author":"Emanuele","year":"1996","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/diacare.23.10.1478","article-title":"Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators","volume":"23","author":"Levin","year":"2000","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jdiacomp.2004.12.002","article-title":"Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus","volume":"19","author":"Pitale","year":"2005","journal-title":"Journal of Diabetes & its Complications"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2337\/diacare.23.9.1316","article-title":"Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM)","volume":"23","author":"Pitale","year":"2000","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0461|cit461","first-page":"833","article-title":"Comparative study of monocomponent insulins and conventional insulins on the course of diabetic nephropathy. A follow-up study","volume":"38","author":"Viswanathan","year":"1990","journal-title":"Journal of the Association of Physicians of India"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1440-1797.2010.01329.x","article-title":"Anti-inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: a randomized controlled pilot study","volume":"16","author":"Vos","year":"2011","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0463|cit463","first-page":"A4","article-title":"Does insulin have an anti-inflammatory effect in patients with end-stage renal disease on haemodialysis?","volume":"14","author":"Vos","year":"2009","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0464|cit464","first-page":"13","article-title":"Renal protecting effects of pioglitazone in diabetic nephropathy","volume":"24","author":"Wang","year":"2004","journal-title":"Clinical Medicine"},{"issue":"11A","key":"10.1002\/14651858.CD011798.pub2-BIB0465|cit465","first-page":"36","article-title":"Rosiglitazone affects albuminuria in type 2 diabetes","volume":"28","author":"Wang","year":"2005","journal-title":"Journal of Postgraduates of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0466|cit466","first-page":"711","article-title":"Effects of rosiglitazone in type 2 diabetic nephropathy","volume":"21","author":"Wang","year":"2005","journal-title":"Clinical Medicine of China"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0467|cit467","first-page":"692","article-title":"Rosiglitazone affects urinary protein excretory rate and C-reactive protein in diabetic nephropathy","volume":"5","author":"Wang","year":"2005","journal-title":"Zhong Guo Wu Zhen Xue Za Zhi [Chinese Journal of Misdiagnostics]"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0468|cit468","first-page":"808","article-title":"Twenty-two cases diagnosed with diabetic nephropathy treated with pioglitazone combined prostaglandin","volume":"41","author":"Wang","year":"2006","journal-title":"Zheng Zhou Da Xue Xue Bao (Yi Xue Ban) [Journal of Zhengzhou University (Medical Science)]"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0469|cit469","first-page":"95","article-title":"Effect of rosiglitazone in early stage of diabetic nephropathy","volume":"7","author":"Wang","year":"2008","journal-title":"Journal of Clinical and Experimental Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0470|cit470","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM198503073121004","article-title":"Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes","volume":"312","author":"Wiseman","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0471|cit471","first-page":"56","article-title":"Observation of trace urinary protein and C-reactive protein level of pioglitazone treating early diabetic nephropathy","volume":"34","author":"Xu","year":"2005","journal-title":"Chongqin Medicine Journal"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diabres.2011.07.035","article-title":"Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial","volume":"94","author":"Yang","year":"2011","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diabres.2008.09.049","article-title":"Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance","volume":"83","author":"Yokoyama","year":"2009","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0474|cit474","first-page":"1432","article-title":"Clinical observation of treatment effect of enalapril combined rosiglitazone in early stage diabetic nephropathy","volume":"27","author":"Zhang","year":"2007","journal-title":"Zhong Guo Yi Yuan Yao Xue Za Zhi [Chinese Journal of Hospital Pharmacy]"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000337929","article-title":"Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria","volume":"35","author":"Zhang","year":"2012","journal-title":"Kidney & Blood Pressure Research"},{"issue":"14","key":"10.1002\/14651858.CD011798.pub2-BIB0476|cit476","first-page":"1037","article-title":"Effect of rosiglitazone in microalbuminuria in type 2 diabetic nephropathy","volume":"22","author":"Zhao","year":"2007","journal-title":"Clinical Focus"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0477|cit477","first-page":"36","article-title":"The clinical observation of benazepril combined with rosiglitazone in patients with diabetic nephropathy","volume":"34","author":"Zheng","year":"2006","journal-title":"Academic Journal of GuangZhou Medical College"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0478|cit478","first-page":"72","article-title":"Renal protection effects of rosiglitazone in diabetic nephropathy","volume":"6","author":"Zhou","year":"2003","journal-title":"Liaoning Pharmacy and Clinical Remedies"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0479|cit479","first-page":"480","article-title":"Observation of treatment effect of rosiglitazone combined irbesartan","volume":"15","author":"Zhou","year":"2007","journal-title":"Zhong Guo Man Xing Bing Yu Fang Yu Kong Zhi [Chinese Journal of Prevention and Control of Chronic Non-communicable Diseases]"},{"issue":"17","key":"10.1002\/14651858.CD011798.pub2-BIB0480|cit480","first-page":"1845","article-title":"Metformin treatment of early diabetic nephropathy","volume":"28","author":"Zhu","year":"2007","journal-title":"JiLin Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0481|cit481","first-page":"931","article-title":"Observation of curative effect of rosiglitazone on delaying progression of type 2 diabetic nephropathy","volume":"16","author":"Zou","year":"2005","journal-title":"China Pharmacy"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0482|cit482","first-page":"S3","article-title":"Comparable glycaemic control with once weekly dulaglutide versus insulin glargine, both combined with lispro, in type 2 diabetes and chronic kidney disease (AWARD-7) [abstract]","volume":"60","author":"Tuttle","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.12955","article-title":"A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment","volume":"71","author":"Chacra","year":"2017","journal-title":"International Journal of Clinical Practice"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0484|cit484","first-page":"A133","article-title":"Effect of rosiglitazone on arterial function and stiffness in patients with stage 3 to 4 chronic kidney disease [abstract no: 127]","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0485|cit485","unstructured":"Chan D Watts G Irish A Dogra G Rosiglitazone improves inflammation and in vivo marker of endothelial function but not arterial function and stiffness in patients with stage 3 - 4 chronic kidney disease [abstract no: SA181] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0486|cit486","first-page":"A132","article-title":"Rosiglitazone lowers insulin resistance, inflammation and von Willebrand factor in patients with stage 1-4 chronic kidney disease [abstract no: 126]","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0487|cit487","first-page":"A132","article-title":"Safety and tolerability of rosiglitazone in stage 3-4 chronic kidney disease [abstract no: 125]","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011798.pub2-BIB0488|cit488","first-page":"42","article-title":"Impact of rosiglitazone on markers of bone metabolism in chronic kidney disease [abstract no: 060]","volume":"15","author":"Chan","year":"2010","journal-title":"Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1093\/ndt\/gfr049","article-title":"Rosiglitazone does not improve vascular function in subjects with chronic kidney disease","volume":"26","author":"Chan","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2016.06.004","article-title":"Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1","volume":"179","author":"Marso","year":"2016","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00125-017-4422-0","article-title":"DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality","volume":"61","author":"Pieber","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00125-017-4423-z","article-title":"Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"issue":"20","key":"10.1002\/14651858.CD011798.pub2-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","article-title":"Serial measurement of high-sensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)","volume":"135","author":"Cavender","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","article-title":"EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome","volume":"162","author":"White","year":"2011","journal-title":"American Heart Journal"},{"issue":"14","key":"10.1002\/14651858.CD011798.pub2-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/dc16-0303","article-title":"Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"issue":"9982","key":"10.1002\/14651858.CD011798.pub2-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/dom.12444","article-title":"LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations","volume":"17","author":"Daniels","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0500|cit500","first-page":"S8","article-title":"Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER trial [abstract]","volume":"58","author":"Mann","year":"2017","journal-title":"Internist"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD011798.pub2-BIB0501|cit501","first-page":"1B","article-title":"Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial [abstract no: HI-OR01]","volume":"27","author":"Mann","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD011798.pub2-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/HJH.0000000000000890","article-title":"LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial","volume":"34","author":"Petrie","year":"2016","journal-title":"Journal of Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0506|cit506","first-page":"23","article-title":"Liraglutide and renal outcomes in Type 2 diabetes: Results of the 'liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results' (LEADER) trial [abstract]","volume":"34","author":"Poulter","year":"2017","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-016-0153-5","article-title":"LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ","volume":"8","author":"Rutten","year":"2016","journal-title":"Diabetology & metabolic syndrome"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jdiacomp.2016.06.001","article-title":"LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population","volume":"30","author":"Satman","year":"2016","journal-title":"Journal of Diabetes & its Complications"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0509|cit509","first-page":"206","article-title":"Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER trial [abstract]","volume":"24","author":"Sesti","year":"2017","journal-title":"High Blood Pressure and Cardiovascular Prevention"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MPA.0000000000000229","article-title":"LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial","volume":"43","author":"Steinberg","year":"2014","journal-title":"Pancreas"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3747\/pdi.2011.00116","article-title":"Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial","volume":"32","author":"Li","year":"2012","journal-title":"Peritoneal Dialysis International"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0513|cit513","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1479164115579002","article-title":"Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2DTM trial","volume":"12","author":"Groop","year":"2015","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0515|cit515","first-page":"S360","article-title":"Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes: The MARLINA-T2DTM trial [abstract]","volume":"59","author":"Schernthaner","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011798.pub2-BIB0516|cit516","first-page":"60","article-title":"Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes-the MARLINA-T2DTM trial [abstract]","volume":"21","author":"Schernthaner","year":"2016","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0517|cit517","unstructured":"Kashiwagi A Maegawa H Exploratory study to investigate the suppressive effect of oral anti-diabetic drug (tzd) on progression of diabetic nephropathy on Japanese type 2 diabetic patients www.clinicaltrials.gov\/ct2\/show\/NCT00846716"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0518|cit518","first-page":"64","article-title":"The effect of low dose liraglutide on renal inflammation in type 2 diabetic kidney disease: a randomised controlled study [abstract]","volume":"33","author":"Neff","year":"2016","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00125-016-4083-4","article-title":"Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial","volume":"59","author":"Ott","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011798.pub2-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"iii11","DOI":"10.1093\/ndt\/gfv139.03","article-title":"Effects of linagliptin on early alterations of renal endothelial function in patients with type-2 diabetes [abstract]","volume":"30","author":"Schmieder","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0521|cit521","first-page":"S4","article-title":"Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6) [abstract]","volume":"60","author":"Consoli","year":"2017","journal-title":"Diabetologia"},{"issue":"19","key":"10.1002\/14651858.CD011798.pub2-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0523|cit523","first-page":"1175A","article-title":"Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk [abstract]","volume":"66","author":"Sanyal","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0524|cit524","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.12808","article-title":"The effect of liraglutide on renal function: a randomized clinical trial","volume":"19","author":"Scholten","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11A","key":"10.1002\/14651858.CD011798.pub2-BIB0525|cit525","first-page":"55","article-title":"Rosiglitazone's effect to trace urinary protein and C-reactive protein in patients with diabetic nephropathy","volume":"29","author":"Xie","year":"2006","journal-title":"Chinese Journal of Postgraduate Medicine"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0526|cit526","first-page":"S357","article-title":"CARMELINA trial baseline characteristics: A cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk [abstract]","volume":"60","author":"Perkovic","year":"2017","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0527|cit527","first-page":"A344","article-title":"CARMELINA trial baseline characteristics: A cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk [abstract]","volume":"66","author":"Rosenstock","year":"2017","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0528|cit528","unstructured":"NCT02547935 A study to evaluate the effect of dapagliflozin with and without saxagliptin on albuminuria, and to investigate the effect of dapagliflozin and saxagliptin on hba1c in patients with type 2 diabetes and CKD3 www.clinicaltrials.gov\/ct2\/show\/NCT02547935"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0529|cit529","unstructured":"de Boer I Continuous glucose monitoring to assess glycemia in chronic kidney disease - changing glucose management (CANDY-CANE) www.clinicaltrials.gov\/ct2\/show\/NCT02608177"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0530|cit530","first-page":"S1","article-title":"Standards of medical care in diabetes--2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1002\/14651858.CD011798.pub2-BIB0531|cit531","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0532|cit532","unstructured":"Nainggolan L ALECARDIO trial halted for safety Medscape: News and Perspective: www.medscape.com\/viewarticle\/793304"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0533|cit533","doi-asserted-by":"crossref","unstructured":"Andrianesis V Glykofridi S Doupis J The renal effects of SGLT2 inhibitors and a mini-review of the literature Therapeutic Advances in Endocrinology & Metabolism 2016 212 28 28203358","DOI":"10.1177\/2042018816676239"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0534|cit534","unstructured":"McDonald S Excell L Dent H ANZDATA 32nd Annual Report. 2009 Report: Data to 2008. Chapter 2: New patients commencing treatment in 2008 www.anzdata.org.au\/anzdata\/AnzdataReport\/32ndReport\/Ch02.pdf"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0535|cit535","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0272-6386(83)80060-2","article-title":"Drug prescribing in renal failure: dosing guidelines for adults","volume":"3","author":"Bennett","year":"1983","journal-title":"American Journal of Kidney Diseases"},{"issue":"7 Suppl 2","key":"10.1002\/14651858.CD011798.pub2-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/01.ASN.0000070152.11927.4A","article-title":"Prevalence of kidney damage in Australian adults: the AusDiab kidney study","volume":"14","author":"Chadban","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0537|cit537","first-page":"S162","article-title":"The CARI Guidelines. Prevention and management of chronic kidney disease in type 2 diabetes","volume":"15 Suppl 1","author":"Chadban","year":"2010","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0538|cit538","first-page":"73","article-title":"Management of drugs affecting blood glucose in diabetic patients with renal failure","volume":"26 Suppl 4","author":"Charpentier","year":"2000","journal-title":"Diabetes & Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0539|cit539","doi-asserted-by":"crossref","first-page":"e111543","DOI":"10.1371\/journal.pone.0111543","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS ONE (Electronic Resource]"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0540|cit540","first-page":"A6-7, S6-296","article-title":"Excerpts from the United States Renal Data System 2006 Annual Data Report","volume":"49","author":"Collins","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0541|cit541","first-page":"S1","article-title":"Excerpts from the United States Renal Data System 2007 Annual Data Report","volume":"51","author":"Collins","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD011798.pub2-BIB0542|cit542","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2diabetes.[Erratum appears in Diabetologia. 2009 Nov;52(1):2470 Note: Control Group [added]]","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"14","key":"10.1002\/14651858.CD011798.pub2-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ki.1995.236","article-title":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group","volume":"47","author":"Anonymous","year":"1995","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0546|cit546","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024-5; PMID: 19726779]","volume":"360","author":"Duckworth","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0547|cit547","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL\/min)","volume":"30 Suppl 2","author":"Guideline Development Group","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0549|cit549","unstructured":"US Food Drug Administration Rezulin from the market www.nfb.org\/Images\/nfb\/Publications\/vod\/vsum0003.htm"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0550|cit550","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/sj.ki.5001886","article-title":"Is there a need to optimize glycemic control in hemodialyzed diabetic patients?","volume":"70","author":"Feldt-Rasmussen","year":"2006","journal-title":"Kidney International"},{"issue":"7650","key":"10.1002\/14651858.CD011798.pub2-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD011798.pub2-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0553|cit553","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"15","key":"10.1002\/14651858.CD011798.pub2-BIB0554|cit554","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0555|cit555","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.ajkd.2016.06.014","article-title":"Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta-analysis","volume":"68","author":"Howse","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0556|cit556","unstructured":"International Diabetes Federation IDF Diabetes Atlas. 6th edition. 2013 www.idf.org\/component\/attachments\/attachments.html?id=813&task=download"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).[Erratum appears in Diabetologia. 2013 Mar;56(3):680]","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"issue":"9739","key":"10.1002\/14651858.CD011798.pub2-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0559|cit559","first-page":"30","article-title":"Hemodialysis-induced hypoglycemia in diabetic patients","volume":"54","author":"Jackson","year":"2000","journal-title":"Clinical Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0560|cit560","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009966","article-title":"Glucose lowering therapies for chronic kidney disease and kidney transplantation","author":"Jun","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0561|cit561","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.[Erratum appears in Kidney Int. 2011 Nov;80(9):1000], [Erratum appears in Kidney Int. 2011 Nov 1;80(9):1000; PMID: 30036909]","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney International"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0562|cit562","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0563|cit563","first-page":"850","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.[Erratum appears in Am J Kidney Dis. 2013 Jun;61(6):1049]","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0564|cit564","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ndt\/15.1.65","article-title":"Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis","volume":"15","author":"Kobayashi","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0565|cit565","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/diacare.23.10.1478","article-title":"Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators","volume":"23","author":"Levin","year":"2000","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0566|cit566","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009966.pub2","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","author":"Lo","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0567|cit567","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1081\/JDI-56608","article-title":"Long-term impact of chronic hemodialysis on glycemic control and serum lipids in insulin-treated type 2 diabetic patients","volume":"27","author":"Loipl","year":"2005","journal-title":"Renal Failure"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"Moen","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0569|cit569","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/diacare.24.5.909","article-title":"Glycemic control is a predictor of survival for diabetic patients on hemodialysis","volume":"24","author":"Morioka","year":"2001","journal-title":"Diabetes Care"},{"issue":"25","key":"10.1002\/14651858.CD011798.pub2-BIB0570|cit570","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"7","key":"10.1002\/14651858.CD011798.pub2-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc05-1887","article-title":"Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study","volume":"29","author":"Oomichi","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/DMSO.S116810","article-title":"Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"10","author":"Orme","year":"2017","journal-title":"Diabetes, Metabolic Syndrome & Obesity Targets & Therapy"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0574|cit574","doi-asserted-by":"crossref","unstructured":"Patel S Gohel K Patel BG A systematic review on effect of canagliflozin in special population Current Diabetes Reviews 2016 211 22 26084476","DOI":"10.2174\/1573399811666150618143948"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0575|cit575","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1681\/ASN.2007020256","article-title":"Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: Data from the PROGRESS Study","volume":"18","author":"Perkovic","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD011798.pub2-BIB0576|cit576","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD011798.pub2-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4065\/83.12.1373","article-title":"Rationale and strategies for early detection and management of diabetic kidney disease","volume":"83","author":"Radbill","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0578|cit578","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.24.5.886","article-title":"Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients","volume":"24","author":"Rave","year":"2001","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD011798.pub2-BIB0579|cit579","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","article-title":"Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials","volume":"43","author":"Rehman","year":"2017","journal-title":"Diabetes & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011798.pub2-BIB0580|cit580","first-page":"A288","article-title":"Sodium glucose co-transporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systemic review and meta-analysis [abstract]","volume":"65","author":"Ruanpeng","year":"2016","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0581|cit581","doi-asserted-by":"crossref","unstructured":"Scheen AJ Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease Clinical Pharmacokinetics 2015 691 708 25805666","DOI":"10.1007\/s40262-015-0264-4"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0582|cit582","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0583|cit583","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD011798.pub2-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2009.12.038","article-title":"Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis","volume":"55","author":"Shurraw","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"21","key":"10.1002\/14651858.CD011798.pub2-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1001\/archinternmed.2011.537","article-title":"Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study","volume":"171","author":"Shurraw","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0586|cit586","doi-asserted-by":"crossref","unstructured":"Shyangdan DS Uthman OA Waugh N SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis BMJ Open 2016 e009417 26911584","DOI":"10.1136\/bmjopen-2015-009417"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"205031211665909","DOI":"10.1177\/2050312116659090","article-title":"An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease","volume":"4","author":"Singh-Franco","year":"2016","journal-title":"SAGE Open Medicine"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0588|cit588","doi-asserted-by":"crossref","unstructured":"Storgaard H Gluud LL Bennett C Grondahl MF Christensen MB Knop FK Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis PLoS ONE (Electronic Resource] 2016 e0166125 27835680","DOI":"10.1371\/journal.pone.0166125"},{"issue":"4","key":"10.1002\/14651858.CD011798.pub2-BIB0589|cit589","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"9131","key":"10.1002\/14651858.CD011798.pub2-BIB0590|cit590","first-page":"857","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug 14;354(9178):602]","volume":"352","author":"Anonynous","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"10.1002\/14651858.CD011798.pub2-BIB0591|cit591","first-page":"854","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1998 Nov 7;352(9139):1558]","volume":"352","author":"Anonymous","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2007","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000454683","article-title":"Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials","volume":"136","author":"Walker","year":"2017","journal-title":"Nephron"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.ki.5001789","article-title":"Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival","volume":"70","author":"Williams","year":"2006","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD011798.pub2-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/ndt\/12.10.2105","article-title":"Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis","volume":"12","author":"Wu","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"key":"#cr-split#-10.1002\/14651858.CD011798.pub2-BIB0596|cit596.1","doi-asserted-by":"crossref","unstructured":"Wu JH Foote C Blomster J Toyama T Perkovic V Sundstrom J Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.[Erratum appears in Lancet Diabetes Endocrinol. 2016 Sep;4(9):e9","DOI":"10.1016\/S2213-8587(16)00052-8"},{"key":"#cr-split#-10.1002\/14651858.CD011798.pub2-BIB0596|cit596.2","unstructured":"PMID: 27174817] The Lancet Diabetes & Endocrinology 2016 411 9 27009625"},{"issue":"2","key":"10.1002\/14651858.CD011798.pub2-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/00325481.2017.1255537","article-title":"Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review","volume":"129","author":"Xu","year":"2017","journal-title":"Postgraduate Medicine"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0598|cit598","doi-asserted-by":"crossref","unstructured":"Zaccardi F Webb DR Htike ZZ Youssef D Khunti K Davies MJ Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis Diabetes, Obesity & Metabolism 2016 783 94 27059700","DOI":"10.1111\/dom.12670"},{"key":"10.1002\/14651858.CD011798.pub2-BIB0599|cit599","doi-asserted-by":"crossref","unstructured":"Zanoli L Granata A Lentini P Rastelli S Fatuzzo P Rapisarda F Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease Thescientificworldjournal 2015 317507 25785281","DOI":"10.1155\/2015\/317507"},{"issue":"6","key":"10.1002\/14651858.CD011798.pub2-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD011798.pub2-BIB0601|cit601","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011798.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:31:23Z","timestamp":1662132683000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD011798.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":602,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011798.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]}}}